Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY102
- Development stage
- Phase 1
- Lead developer
- Qingdao Marine Biomedical Research Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LY102 is an oral marine-derived small molecule drug candidate under development for the treatment of chronic hepatitis B. Jointly developed by the Ocean University of China, Qingdao Marine Biomedicine Research Institute, and Qingdao Haiji Biopharmaceutical, LY102 is designed to exert a dual therapeutic effect by targeting both the hepatitis B virus and host factors. It has been shown to significantly reduce the expression of hepatitis B surface antigen (HBsAg) while promoting the repair of liver injury and inhibiting inflammation. LY102 is currently in Phase 1 clinical development in China.
Beyond the preview
Go deeper on LY102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY102.